Oil Prices Rise as Hormuz Risks Offset IEA Stock Release 
US, EU Push for Action Against Asia’s Excess Factory Capacity 
Oil Prices Trim Gains After Trump Rules Out Iran Strikes Before Midterms 
Wall Street Falls as Fed Minutes Signal Another Rate Hike 
European Stocks Fall as Oil Rises Ahead of Fed Minutes 
US Stock Futures Flat as Fed Minutes, Earnings Loom 
Gold Prices Rise as Hormuz Tensions Fuel Inflation Risks 
Japan Real Wages Rise 1.5%, Supporting BOJ Rate Hikes 
Deere, CNH and AGCO Stocks Fall as FTC Launches Farm Equipment Probe 
Mike Rogers Calls for End to US-Canada Tariff War 
US Treasury Yields Ease After Strong 10-Year Auction as Global Bonds Struggle 
US-Led Coalition Targets Global Factory Overcapacity 
RBI Raises Repo Rate to 5.50% in Hawkish Shift on Inflation Risks 
Indian Stocks Fall as RBI Hikes Rates to 5.50% 
Crypto Market Selloff Wipes Out $100B as Bitcoin Falls Below $83K 
US Dollar Hits 18-Month High as Fed Signals More Rate Hikes 
Dollar Near 18-Month High as Euro, Yen and Pound Weaken 
Add as a preferred source on Google
China’s WuXi AppTec has signed an agreement to sell its gene therapy manufacturing arm, WuXi Advanced Therapies, to U.S.-based Altaris LLC, following mounting restrictions on Chinese firms in the United States over national security concerns. The deal also includes Oxford Genetics in the UK.
WuXi AppTec Sells Gene Therapy Unit Amid US Restrictions
The Chinese company WuXi AppTec announced on Tuesday that its subsidiaries have inked a contract with the private equity firm Altaris LLC, which is based in the United States, for the sale of its cell and gene therapy manufacturing unit, WuXi Advanced Therapies, for an amount that has not been disclosed.
Due to worries regarding national security, the corporation, along with other Chinese businesses, has been at the focus of new regulations that have been enacted in the United States with the intention of restricting their businesses in the United States, Investing.com shares.
US Legislation Targets Chinese Companies Over National Security Concerns
In September, the House of Representatives of the United States of America enacted a bill that would bar the federal government from entering into contracts with specified companies and those that do business with those companies.
The laws are intended to protect the personal health and genetic information of Americans from foreign adversaries.
Shift in US Pharma and Biotech Supply Chains
Additionally, they intend to encourage pharmaceutical and biotechnology businesses in the United States to reduce their reliance on China for a variety of activities, including the manufacturing of medicinal ingredients and early research.
The United Kingdom-based operating company of the WuXi ATU business, Oxford Genetics, will be sold to Altaris LLC, according to a statement made by WuXi.
Altaris declined to comment further than the information that was provided, while WuXi AppTec did not react to a request for comment made by Reuters by the company.
